Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Zuranolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Sage Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zurzuvae (zuranolone), the first and only oral, once-daily, 14-day treatment course, has shown to provide rapid improvements in depressive symptoms at Day 15 and as early as Day 3 for women with PPD.
Product Name : SAGE-217
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 14, 2023
Lead Product(s) : Zuranolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Sage Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zuranolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Biogen
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zurzuvae (zuranolone), a neuroactive steroid GABA-A receptor positive allosteric modulator, is the first and only oral, once-daily, 14-day treatment approved by FDA, that can provide rapid improvements in depressive symptoms for women with postpartum dep...
Product Name : SAGE-217
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 31, 2023
Lead Product(s) : Zuranolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Biogen
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zuranolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Sage Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone
Details : SAGE-217 (zuranolone) is an oral neuroactive steroid (NAS) GABA-A receptor positive allosteric modulator (PAM). Currently being developed for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).
Product Name : SAGE-217
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 03, 2023
Lead Product(s) : Zuranolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Sage Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zuranolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Biogen
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SAGE-217 (zuranolone) is an oral neuroactive steroid (NAS) GABA-A receptor positive allosteric modulator (PAM). Currently being developed for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).
Product Name : SAGE-217
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 02, 2023
Lead Product(s) : Zuranolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Biogen
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zuranolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Sage Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zurzuvae (zuranolone), a neuroactive steroid GABA-A receptor positive allosteric modulator, is the first and only oral, once-daily, 14-day treatment approved by FDA, that can provide rapid improvements in depressive symptoms for women with postpartum dep...
Product Name : SAGE-217
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 08, 2023
Lead Product(s) : Zuranolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Sage Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zuranolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Sage Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zuranolone 50 mg demonstrated a clinically meaningful and statistically significant improvement in depressive symptoms at Day 15, the primary endpoint, and at Days 3, 28, and 45, key secondary endpoints as previously reported.
Product Name : SAGE-217
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 17, 2022
Lead Product(s) : Zuranolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Sage Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zuranolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Biogen
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zuranolone (SAGE-217/BIIB125) is a once-daily, 14-day, investigational drug in development for the treatment of major depressive disorder (MDD) and postpartum depression (PPD).
Product Name : SAGE-217
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 19, 2022
Lead Product(s) : Zuranolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Biogen
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zuranolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Sage Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SAGE-217 (zuranolone) is a once-daily, 14-day, investigational drug in development for the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an oral neuroactive steroid (NAS) GABA-A receptor positive allosteric m...
Product Name : SAGE-217
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 12, 2022
Lead Product(s) : Zuranolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Sage Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zuranolone,Escitalopram Oxalate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Biogen
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : At the Day 3 primary endpoint, SAGE-217/BIIB125 (Zuranolone), investigational oral neuroactive steroid GABA-A receptor-positive allosteric modulator, 50 mg co-initiated with a standard of care antidepressant showed a statistically significant reduction i...
Product Name : SAGE-217
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 16, 2022
Lead Product(s) : Zuranolone,Escitalopram Oxalate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Biogen
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zuranolone
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Biogen
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SAGE-217/BIIB125 (zuranolone) is a once-daily, two-week, investigational drug in development for treatment of major depressive disorder and postpartum depression. Zuranolone is an investigational oral neuroactive steroid (NAS) GABA-A receptor positive al...
Product Name : SAGE-217
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 05, 2022
Lead Product(s) : Zuranolone
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Biogen
Deal Size : Inapplicable
Deal Type : Inapplicable